Cocrystal Pharma, Inc.
For the period ended Mar 31, 2026. Filed Mar 31, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Mar 31, 2026 · Filed Mar 31, 2026
Use the contents to explore the available documents and sections.
Contents
EX-99.1 · Norovirus Program
Norovirus Program
Norovirus is a common, highly contagious virus that afflicts people of all ages and causes symptoms of acute gastroenteritis including nausea, vomiting, stomach pain and diarrhea, as well as fatigue, fever and dehydration. There are currently no effective treatments or vaccines for norovirus, and the ability to curtail outbreaks is inadequate.
With 685 million global cases annually and a $60 billion worldwide economic impact, norovirus represents one of healthcare’s most pressing unmet needs. In the U.S., noroviruses are responsible for an estimated 21 million infections annually, including an estimated 109,000 hospitalizations, 465,000 emergency department visits and 900 deaths. The annual burden of norovirus to the U.S. is estimated at$10.6 billion. In the developing world, each year noroviruses are responsible forup to 1.1 million hospitalizations and 218,000 pediatric deaths.
Oral protease inhibitorCDI-988for the treatment of noroviruses and coronaviruses:Our novel, broad-spectrum 3CL protease inhibitorCDI-988 is designed as a potential treatment for noroviruses and coronaviruses.CDI-988 has shownin vitro activity against multiple norovirus strains.
| ○ | In April 2025 we announced that CDI-988 showed superior broad-spectrum antiviral activity against the norovirus GII.17 strain, the most prevalent strain in the U.S. and Europe in 2024-2025. |
|---|---|
| ○ | In August 2025 we presented favorable Phase 1 safety and tolerability data from all CDI-988 doses, including a high-dose 1200 mg cohort, at the 2025 Military Health System Research Symposium (MHSRS). |
| ○ | In September 2025 we discussed CDI-988’s scientific foundation and clinical progress in an oral presentation at the 9th International Calicivirus Conference, the leading calicivirus scientific meeting. |
| ○ | In September 2025 we received a Study May Proceed Letter from the FDA to conduct a Phase 1b challenge study in the U.S. evaluating CDI-988 as a norovirus preventive and treatment. |
| ○ | In March 2026 we enrolled the first subjects in our Phase 1b challenge study with the initial cohort evaluating the infectivity rate of the GII.2 challenge inoculum, and subsequent cohorts to be orally administered CDI-988 or placebo. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.